Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07235046 · ClinicalTrials.gov registry record · Phase 2
A Study of DII235 in Adults With Elevated Lipoprotein(a)
A Phase 2 study of Lipoprotein Disorder, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT07235046: Recruiting Phase 2 study of Lipoprotein Disorder, sponsored by Novartis Pharmaceuticals.
NCT07235046 is a Phase 2 study of Lipoprotein Disorder that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 200 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07235046, a Phase 2 study of Lipoprotein Disorder, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to determine the safety and efficacy of DII235 in adults with elevated lipoprotein(a).
Primary Outcome
Time averaged change from baseline in log Lp(a) measured between Day 60 and Day 180, defined as the area under the curve (AUC) between the Day 60 Visit date and the Day 180 Visit date, divided by the duration between the two visit dates.
Conditions Studied
Interventions
- DRUG Saline
- DRUG DII235
Study Locations (20)
Florida
- Excel Medical Clinical Trials LLC - Boca Raton
- Zenith Clinical Research - Hollywood
- Jacksonville Center for Clinical Research - Jacksonville
- Flourish Res Acq LLC North Miami - Miami
- Inpatient Research Clinical LLC - Miami Lakes
- Inpatient Research Clinical LLC - Miami Lakes
- Ocala Cardiovascular Research - Ocala
- SEC Clinical Research - Pensacola
- Cardiology Partners Clinical Research Institute - Wellington
Alabama
- Parkway Medical Center - Birmingham
- Heart Center Research Llc - Huntsville
California
- National Heart Institute - Beverly Hills
- Alliance Clinical - Canoga Park
Louisiana
- CV Ins of the South - Lafayette
- Monroe Research Llc - West Monroe
Arkansas
- Cardiology and Medicine Clinic PA - Little Rock
Georgia
- Atlanta Heart Specialists LLC - Tucker
Illinois
- AMR Chicago - Oak Brook
Kansas
- Alliance for Multispecialty Research - Wichita
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-12-05 |
| Est. Completion | 2028-09-08 |
| Phase | Phase 2 |
What NCT07235046 shows while recruiting
NCT07235046 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher).
The record links to 1 condition, with Lipoprotein Disorder appearing as the primary indexed condition, and to 2 interventions - of which Saline is the first listed.
NCT07235046 names 20 study sites across 9 states, led by Florida, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT07235046 about?
NCT07235046 is a clinical study titled "A Study of DII235 in Adults With Elevated Lipoprotein(a)". The main purpose of this study is to determine the safety and efficacy of DII235 in adults with elevated lipoprotein(a).
What is the current status of trial NCT07235046?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-12-05. Estimated completion is 2028-09-08.
What conditions does trial NCT07235046 study?
This clinical trial studies the following conditions: Lipoprotein Disorder.
What interventions are being tested in trial NCT07235046?
The interventions under investigation include: Saline (DRUG), DII235 (DRUG).
Who is sponsoring clinical trial NCT07235046?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07235046 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lipoprotein Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07235046's enrollment target sits among peer trials
200 304th of 2000 higher than 1,652 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI